Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-bein...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
2005
|
| _version_ | 1826302057756229632 |
|---|---|
| author | McMurray, J Cohen-Solal, A Dietz, R Eichhorn, E Erhardt, L Hobbs, F Krum, H Maggioni, A McKelvie, R Piña, I Soler-Soler, J Swedberg, K |
| author_facet | McMurray, J Cohen-Solal, A Dietz, R Eichhorn, E Erhardt, L Hobbs, F Krum, H Maggioni, A McKelvie, R Piña, I Soler-Soler, J Swedberg, K |
| author_sort | McMurray, J |
| collection | OXFORD |
| description | Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines. |
| first_indexed | 2024-03-07T05:41:45Z |
| format | Journal article |
| id | oxford-uuid:e5d07cf0-ccb1-49e7-abc8-7a1f5efc651e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:41:45Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:e5d07cf0-ccb1-49e7-abc8-7a1f5efc651e2022-03-27T10:26:35ZPractical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e5d07cf0-ccb1-49e7-abc8-7a1f5efc651eEnglishSymplectic Elements at Oxford2005McMurray, JCohen-Solal, ADietz, REichhorn, EErhardt, LHobbs, FKrum, HMaggioni, AMcKelvie, RPiña, ISoler-Soler, JSwedberg, KSurveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines. |
| spellingShingle | McMurray, J Cohen-Solal, A Dietz, R Eichhorn, E Erhardt, L Hobbs, F Krum, H Maggioni, A McKelvie, R Piña, I Soler-Soler, J Swedberg, K Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title_full | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title_fullStr | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title_full_unstemmed | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title_short | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. |
| title_sort | practical recommendations for the use of ace inhibitors beta blockers aldosterone antagonists and angiotensin receptor blockers in heart failure putting guidelines into practice |
| work_keys_str_mv | AT mcmurrayj practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT cohensolala practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT dietzr practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT eichhorne practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT erhardtl practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT hobbsf practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT krumh practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT maggionia practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT mckelvier practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT pinai practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT solersolerj practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice AT swedbergk practicalrecommendationsfortheuseofaceinhibitorsbetablockersaldosteroneantagonistsandangiotensinreceptorblockersinheartfailureputtingguidelinesintopractice |